The Metastatic Transitional (Urothelial) Tract Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Metastatic Transitional (Urothelial) Tract Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Metastatic Transitional (Urothelial) Tract Cancer. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Metastatic Transitional (Urothelial) Tract Cancer and features dormant and discontinued products.
GlobalData tracks 122 drugs in development for Metastatic Transitional (Urothelial) Tract Cancer by 98 companies/universities/institutes. The top development phase for Metastatic Transitional (Urothelial) Tract Cancer is phase ii with 69 drugs in that stage. The Metastatic Transitional (Urothelial) Tract Cancer pipeline has 121 drugs in development by companies and one by universities/ institutes. Some of the companies in the Metastatic Transitional (Urothelial) Tract Cancer pipeline products market are: Bristol-Myers Squibb, Merck and AstraZeneca.
The key targets in the Metastatic Transitional (Urothelial) Tract Cancer pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274), and Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1).
The key mechanisms of action in the Metastatic Transitional (Urothelial) Tract Cancer pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with 14 drugs in Pre-Registration. The Metastatic Transitional (Urothelial) Tract Cancer pipeline products include 14 routes of administration with the top ROA being Intravenous and 12 key molecule types in the Metastatic Transitional (Urothelial) Tract Cancer pipeline products market including Small Molecule, and Monoclonal Antibody.
Metastatic Transitional (Urothelial) Tract Cancer overview
Metastatic transitional (urothelial) tract cancer refers to a cancer that has originated in the transitional epithelium, which lines the urinary tract, including the bladder, ureters, and renal pelvis, and has spread to distant parts of the body. This type of cancer is often associated with urothelial carcinoma, the most common form of bladder cancer. Metastatic urothelial cancer is considered advanced and can spread to lymph nodes, bones, liver, or other organs. Diagnosis involves imaging studies, biopsies, and other tests to determine the extent of the disease. Treatment options may include chemotherapy, immunotherapy, targeted therapies, and, in some cases, surgery. The prognosis for metastatic urothelial cancer can vary based on factors such as the extent of metastasis, the response to treatment, and the overall health of the individual.
For a complete picture of Metastatic Transitional (Urothelial) Tract Cancer’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
